Non Small Cell Lung Cancer - Immunotherapy - KMT2C mutation + BCOR mutation + KDM5C mutation

Association details:

Biomarker:	KMT2C mutation + BCOR mutation + KDM5C mutation
Cancer:	Non Small Cell Lung Cancer
Drug Class:	Immunotherapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

Cancers (Basel)

Title:

Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Published date:

06/06/2022

Excerpt:

Analysis of seven ICB-treated NSCLC cohorts revealed that mutations of three chromatin remodeling-related genes, including KMT2C, BCOR and KDM5C, were significantly associated with ICB response, and combined mutations of these three genes further enhance this association. NSCLC patients with KMT2C/BCOR/KDM5C mutations had comparable clinical outcomes to TMB-high patients in terms of objective response rate, durable clinical benefit and overall survival.

DOI:

https://doi.org/10.3390/cancers14112816